Mel Greaves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mel Greaves has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Maria Socorro Pombo-De-Oliveira
Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
8 shared publications - Frederik van Delft
Newcastle Hospitals NHS Foundation Trust, Newcastle, UK
7 shared publications - Eleni Petridou
Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece
6 shared publications - Evangelia Ntzani
Department of Hygiene and Epidemiology, School of Health Sciences, University of Ioannina School of Medicine, Greece
6 shared publications - Flávio Henrique Paraguassu Braga
National Placental and Umbilical Cord Blood Bank, INCA, MS, Rio de Janeiro, Brazil
6 shared publications Giovanni Cazzaniga
Centro Ricerca M. Tettamanti, University of Milano-Bicocca, Monza, Italy
6 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Timing of microbial exposure and risk of infectionpromoted acute lymphoblastic leukaemia
- 16 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessTiming of microbial exposure and risk of infectionpromoted acute lymphoblastic leukaemia
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Flow diagram summarizing the cases-control process
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Flow diagram summarizing the cases-control process
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Subgroup analyses among non-breastfed children
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Subgroup analyses among non-breastfed children
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Simulation derived logistic regression models
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Simulation derived logistic regression models
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Background:Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been associated with early-life exposures, including birth by cesarean section (C-section), and a deficit of social exposure (first child). These exposures as proxies for microbiome acquisition in infancy are essential to prime the immune system and restrain later dysregulated immune responses that can trigger ALL in susceptible individuals. We tested risk factors pertaining to immune stimulation that may impact BCP-ALL development.Methods:Cases comprised 1,126 children (0–12 years) with ALL (BCP-ALL: 78.5%) from the EMiLI study group in Brazil (2002–2020). Age- and sex-matched controls (n = 2,252) were randomly selected from healthy children whose mothers participated in the National Placental and Umbilical Cord Blood Bank donation. Multiple logistic regression was run fitted and adjusted for selected covariates models.Results:C-section delivery was associated with increased risk for ALL [odds ratio (OR) ALL: 1.10; 95% confidence intervals (CI), 1.04–1.15; ORBCP-ALL: 1.09; 95% CI, 1.03–1.14], as well as being the firstborn child. Interaction analysis showed a significant effect of first birth on the observed C-section associations (P < 0.0001). Indeed, high-risk children, namely, firstborn children delivered via C-section were at increased risk for ALL (OR: 2.33; 95% CI, 2.40–4.84) compared with non-first, vaginally born children. An increased risk was found for firstborn children delivered by C-section and non-breastfed with ALL (ORALL: 2.32; 95% CI, 1.27–4.24; ORBCP-ALL: 2.37; 95% CI, 1.18–4.76).Conclusions:Our observations are in accord with the prediction that exposures determining microbiome composition and adrenal pathway in infancy contribute to the risk of BCP-ALL.Impact:These findings encourage the exploration of potential preventive interventions.See related commentary by Wiemels and Gallant, p. 292
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Background:Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been associated with early-life exposures, including birth by cesarean section (C-section), and a deficit of social exposure (first child). These exposures as proxies for microbiome acquisition in infancy are essential to prime the immune system and restrain later dysregulated immune responses that can trigger ALL in susceptible individuals. We tested risk factors pertaining to immune stimulation that may impact BCP-ALL development.Methods:Cases comprised 1,126 children (0–12 years) with ALL (BCP-ALL: 78.5%) from the EMiLI study group in Brazil (2002–2020). Age- and sex-matched controls (n = 2,252) were randomly selected from healthy children whose mothers participated in the National Placental and Umbilical Cord Blood Bank donation. Multiple logistic regression was run fitted and adjusted for selected covariates models.Results:C-section delivery was associated with increased risk for ALL [odds ratio (OR) ALL: 1.10; 95% confidence intervals (CI), 1.04–1.15; ORBCP-ALL: 1.09; 95% CI, 1.03–1.14], as well as being the firstborn child. Interaction analysis showed a significant effect of first birth on the observed C-section associations (P < 0.0001). Indeed, high-risk children, namely, firstborn children delivered via C-section were at increased risk for ALL (OR: 2.33; 95% CI, 2.40–4.84) compared with non-first, vaginally born children. An increased risk was found for firstborn children delivered by C-section and non-breastfed with ALL (ORALL: 2.32; 95% CI, 1.27–4.24; ORBCP-ALL: 2.37; 95% CI, 1.18–4.76).Conclusions:Our observations are in accord with the prediction that exposures determining microbiome composition and adrenal pathway in infancy contribute to the risk of BCP-ALL.Impact:These findings encourage the exploration of potential preventive interventions.See related commentary by Wiemels and Gallant, p. 292
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Suplementary Table S1 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Multiple logistic regression T-ALL
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuplementary Table S1 from The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia
Multiple logistic regression T-ALL
- Open Access
- 3 April 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (10) , 2255-2257
Risk of leukemia in twins
- 3 April 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (10) , 2255-2257
Open AccessRisk of leukemia in twins
- Open Access
- 25 September 2023
- Published by Springer Nature in BMC Ecology and Evolution
- Vol. 23 (1) , 1-11
Convergent TP53 loss and evolvability in cancer
Cancer cell populations evolve by a stepwise process involving natural selection of the fittest variants within a tissue ecosystem context and as modified by therapy. Genomic scrutiny of patient samples reveals an extraordinary diversity of mutational profiles both between patients with similar cancers and within the cancer cell population of individual patients. Does this signify highly divergent evolutionary trajectories or are there repetitive and predictable patterns?Major evolutionary innovations or adaptations in different species are frequently repeated, or convergent, reflecting both common selective pressures and constraints on optimal solutions. We argue this is true of evolving cancer cells, especially with respect to the TP53 gene. Functional loss variants in TP53 are the most common genetic change in cancer. We discuss the likely microenvironmental selective pressures involved and the profound impact this has on cell fitness, evolvability and probability of subsequent drug resistance.
- 25 September 2023
- Published by Springer Nature in BMC Ecology and Evolution
- Vol. 23 (1) , 1-11
Open AccessConvergent TP53 loss and evolvability in cancer
Cancer cell populations evolve by a stepwise process involving natural selection of the fittest variants within a tissue ecosystem context and as modified by therapy. Genomic scrutiny of patient samples reveals an extraordinary diversity of mutational profiles both between patients with similar cancers and within the cancer cell population of individual patients. Does this signify highly divergent evolutionary trajectories or are there repetitive and predictable patterns?Major evolutionary innovations or adaptations in different species are frequently repeated, or convergent, reflecting both common selective pressures and constraints on optimal solutions. We argue this is true of evolving cancer cells, especially with respect to the TP53 gene. Functional loss variants in TP53 are the most common genetic change in cancer. We discuss the likely microenvironmental selective pressures involved and the profound impact this has on cell fitness, evolvability and probability of subsequent drug resistance.
- 24 August 2023
- Published by Springer Nature in Nature Ecology & Evolution
- Vol. 7 (11) , 1761-1770
Evolutionary determinants of curability in cancer
The emergence of drug-resistant cells, most of which have a mutated TP53 gene, prevents curative treatment in most advanced and common metastatic cancers of adults. Yet, a few, rarer malignancies, all of which are TP53 wild type, have high cure rates. In this Perspective, we discuss how common features of curable cancers offer insights into the evolutionary and developmental determinants of drug resistance. Acquired loss of TP53 protein function is the most common genetic change in cancer. This probably reflects positive selection in the context of strong ecosystem pressures including microenvironmental hypoxia. Loss of TP53’s functions results in multiple fitness benefits and enhanced evolvability of cancer cells. TP53-null cells survive apoptosis, and tolerate potent oncogenic signalling, DNA damage and genetic instability. In addition, critically, they provide an expanded pool of self-renewing, or stem, cells, the primary units of evolutionary selection in cancer, making subsequent adaptation to therapeutic challenge by drug resistance highly probable. The exceptional malignancies that are curable, including the common genetic subtype of childhood acute lymphoblastic leukaemia and testicular seminoma, differ from the common adult cancers in originating prenatally from embryonic or fetal cells that are developmentally primed for TP53-dependent apoptosis. Plus, they have other genetic and phenotypic features that enable dissemination without exposure to selective pressures for TP53 loss, retaining their intrinsic drug hypersensitivity.
- 24 August 2023
- Published by Springer Nature in Nature Ecology & Evolution
- Vol. 7 (11) , 1761-1770
Evolutionary determinants of curability in cancer
The emergence of drug-resistant cells, most of which have a mutated TP53 gene, prevents curative treatment in most advanced and common metastatic cancers of adults. Yet, a few, rarer malignancies, all of which are TP53 wild type, have high cure rates. In this Perspective, we discuss how common features of curable cancers offer insights into the evolutionary and developmental determinants of drug resistance. Acquired loss of TP53 protein function is the most common genetic change in cancer. This probably reflects positive selection in the context of strong ecosystem pressures including microenvironmental hypoxia. Loss of TP53’s functions results in multiple fitness benefits and enhanced evolvability of cancer cells. TP53-null cells survive apoptosis, and tolerate potent oncogenic signalling, DNA damage and genetic instability. In addition, critically, they provide an expanded pool of self-renewing, or stem, cells, the primary units of evolutionary selection in cancer, making subsequent adaptation to therapeutic challenge by drug resistance highly probable. The exceptional malignancies that are curable, including the common genetic subtype of childhood acute lymphoblastic leukaemia and testicular seminoma, differ from the common adult cancers in originating prenatally from embryonic or fetal cells that are developmentally primed for TP53-dependent apoptosis. Plus, they have other genetic and phenotypic features that enable dissemination without exposure to selective pressures for TP53 loss, retaining their intrinsic drug hypersensitivity.
- 6 June 2023
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 23 (8) , 565-576
Gut microbiome immaturity and childhood acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Here, we map emerging evidence suggesting that children with ALL at the time of diagnosis may have a delayed maturation of the gut microbiome compared with healthy children. This finding may be associated with early-life epidemiological factors previously identified as risk indicators for childhood ALL, including caesarean section birth, diminished breast feeding and paucity of social contacts. The consistently observed deficiency in short-chain fatty-acid-producing bacterial taxa in children with ALL has the potential to promote dysregulated immune responses and to, ultimately, increase the risk of transformation of preleukaemic clones in response to common infectious triggers. These data endorse the concept that a microbiome deficit in early life may contribute to the development of the major subtypes of childhood ALL and encourage the notion of risk-reducing microbiome-targeted intervention in the future.
- 6 June 2023
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 23 (8) , 565-576
Gut microbiome immaturity and childhood acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Here, we map emerging evidence suggesting that children with ALL at the time of diagnosis may have a delayed maturation of the gut microbiome compared with healthy children. This finding may be associated with early-life epidemiological factors previously identified as risk indicators for childhood ALL, including caesarean section birth, diminished breast feeding and paucity of social contacts. The consistently observed deficiency in short-chain fatty-acid-producing bacterial taxa in children with ALL has the potential to promote dysregulated immune responses and to, ultimately, increase the risk of transformation of preleukaemic clones in response to common infectious triggers. These data endorse the concept that a microbiome deficit in early life may contribute to the development of the major subtypes of childhood ALL and encourage the notion of risk-reducing microbiome-targeted intervention in the future.